Compugen Ltd. (CW9.F)
| Previous Close | 5.05 |
| Open | 5.15 |
| Bid | 0.00 x 40000 |
| Ask | 0.00 x 40000 |
| Day's Range | 5.05 - 5.15 |
| 52 Week Range | 5.05 - 16.00 |
| Volume | |
| Avg. Volume | 249 |
| Market Cap | 432.352M |
| Beta (5Y Monthly) | 2.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.86 |
PR NewswireCompugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.
PR NewswireCompugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects' link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for
PR NewswireCompugen to Participate in Two Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming investor conferences in April:
